VolitionRx Limited announced its Nu.Q(R) Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation (Heska). The Nu.Q(R) test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference. Heska's Nu.Q(R) Canine Cancer Screen and Monitor Test will operate on Heska's proprietary Element i+(R) Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.711 USD | -4.83% | -5.20% | -0.84% |
May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.84% | 61.88M | |
-26.63% | 9.41B | |
+29.21% | 2.9B | |
-14.31% | 2.16B | |
-19.19% | 1.7B | |
+66.79% | 1.51B | |
+28.88% | 814M | |
-1.97% | 760M | |
-29.29% | 529M | |
+5.17% | 312M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Limited's Nu.Q(R) Vet Cancer Test Now Available for Pre-Order At the Point-Of-Care Through Heska Corporation